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patients having dilated and GHLV with signiﬁcant left ventricu-
lar dysfunction without documented CAD before. EF% was com-
puted by Simpson's method. Epidemiological data and details of
risk factors were studied. CAG was done in all patients. Both
femoral and radial access taken. Treatment plan was modiﬁed
after CAG and viability study results depending upon the
CAD status. Follow up results at the end of four month were
analyzed.
Results: Out of 30 patients with dilated and GHLV with severe left
ventricular dysfunction, majority of patient (13) belong to age
group 40–49 years (45%) 21 patients had normal CAG (60%) and
5 patients had signiﬁcant CAD (20%). A total of 3 patients under-
went CABG and 1 patient had undergone angioplasty. Only
2 patients developed mild renal dysfunction and improved on
follow up.
Conclusions: CAD was seen in 20% of patients with dilated and
GHLV. CAG is safe even up to LVEF of as low as 20%. The triad of low
EF, signiﬁcant CAD and viable myocardium provides favorable
prognosis. Mild CAD needs optimized medication.
Limiting factors for optimal medical
therapy of patients with heart failure
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Kims Hospital, Trivandrum, Kerala, India
Angiotensin-converting enzyme (ACE) and beta blockers are the drugs
which decrease mortality and increase longevity in patients with
heart failure.
Aims and objects: The incidence of heart failure in India is increas-
ing and it affects relatively younger patients. Present study aims to
identify the limiting factors in giving optimal medical manage-
ment in patients with heart failure.
Subjects and methods: This prospective descriptive study was
done at Kerala Institute of Medical Sciences Trivandrum, over a
2 years period from 1st June 2012. Three hundred consecutive
patients with NYHA class 3 or 4 with various etiology of heart
failure were identiﬁed and then all treated patients were analyzed.
Results: Of the 300 patients, 69% (n – 208) were males and 31% (n –
92) were females. Below 70 years there was male predominance of
heart failure but after the age of 70 there was female predomi-
nance.
In our study 94.6% (n = 284) of patients received loop diuretics,
mainly frusemide 55.6% (n – 167) and torsemide 39% (n – 117).
Thiazide diuretics were used infrequently. Metalazonewas used in
8% (n – 24) of patients with loop diuretics when renal failure was
present. Potassium sparing diuretics, spiranolactone were used in
45.6% (n – 137) of patients and eplerenone in 9.3% (n – 28). Only 34%
(n – 104) of patients received ACE or ARB, of which 23.6% (n – 71)
were on ACE inhibitors). ARBs were used by 11% (n – 33) of patients
who were intolerant to ACE inhibitors, mainly due to dry cough.
ACE inhibitors could not be used due to hypotension in 34% (n –
103) of patients and renal failure in 31% (n – 93) of patients. Beta
blockers could be used only in 43% (n – 130) of patients because of
hypotension in 60% (n – 102), bronchial asthma in 20% (34), bra-
dycardia in 15% (25), and chronic obstructive pulmonary disease in
5% (n – 9) of patients.
Conclusion: The mainstay in the management in heart failure
today is ACE inhibitors and beta blockers. We found limitations
in using ACE inhibitors due to comorbidities like renal failure
and hypotension. Beta blockers could be used only in 43% of
patients. Even when the cardiac failure was long standing per-
sistence of contraindications limits the use of ACE/ARB and beta
blockers.
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Outcome study in patients with
ST-segment elevation myocardial
infarction (STEMI) and multivessel
disease (MVD) undergoing primary or
staged PCI
S. Kulkarni, R.K. Saran, V.S. Narain, S.K. Dwivedi,
R. Sethi, S. Chandra, A. Pradhan, G.K. Chaudhary,
P.K. Vishwakarma
Background: Patients of STEMI withMVD are at higher risk of heart
failure, cardiogenic shock and associated with 2 time's higher
mortality during hospitalization. The aim of the study was to
compare the outcome of culprit vessel only PCI and multivessel
PCI during the index procedure or staged in patients with STEMI
and MVD.
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Methods: This was a prospective observational study carried out at
a single tertiary care centre of north India. Sequential patients who
presented with STEMI and at least 1 or more lesions ≥70% in a
major epicardial vessel other than the infarct-related artery
were included. Patients who underwent primary PCI or PCI after
thrombolysis were included. Patients were assigned to 3 different
strategies: culprit vessel angioplasty-only (COR); staged revascu-
larization (SR); and simultaneous treatment of non-IRA (CR).
Results: A total of 109 patients of acute ST elevation MI were
enrolled during a period of 6 months. The mean age was 55.38
 10.0 years, 84 (77.0%) weremen. The COR group included 48 (44%)
patients, the SR group 44 (40%) and the CR group 17 (16%). The
elective PCI in the SR group was performed on average 58  20days
after the initial PCI. After a mean follow-up of 6 months, 9 (8%)
patients died, 3 (2.6%) from cardiac causes. Throughout the follow-
up, 32 (30%) patients experienced at least 1 MACE, 14 (45.0%) in the
COR group, 8 (25.0%) in the SR group and 10 (30%) in the CR group,
p < 0.001. The incidence of inhospital death, repeat revasculariza-
tion and re-hospitalization was signiﬁcantly higher in the COR
group (all p < 0.05), whereas there was no signiﬁcant difference in
re-infarction among the 3 groups. A total of 2 patients (1 each in the
SR and CR group) received both a re-PCI and a subsequent CABG.
Survival free of re-PCI was worse in the COR group compared with
both the CR ( p < 0.001) and the SR group ( p < 0.005), whereas it was
similar between the CR and SR groups ( p < 0.467). Mortality was
more frequent in the COR group although it did not reach statistical
signiﬁcance. The COR group showed a tendency for a worse overall
survival compared with the other groups, without reaching statis-
tical signiﬁcance ( p < 0.151).
Conclusion: Culprit vessel-only PCI was associated with highest
rate of long-term MACE compared with multivessel treatment.
Patients scheduled for staged revascularization experienced a
similar rate of MACE to patients undergoing simultaneous treat-
ment of non-IRA.
Outcome of intra aortic balloon pump
support in patients with cardiogenic
shock during index hospitalization –
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Intra aortic balloon pump (IABP) is an important short term LV
mechanical assist device in patientswith acute LVdysfunction and
cardiogenic shock of varying etiology like acute MI, acute myocar-
ditis, acute valvular regurgitation secondary to infective endiocar-
ditis etc. Recently published 1ABP-SHOCK II trial showed that IABP
in acute MI setting in Intensive Coronary Care Unit (ICCU) does not
have any mortality advantage. In this study, we have studied the
outcome of patients who underwent IABP insertions in our hospi-
tal due to various indications.
Aims and objective: To study the outcome of patients who under-
went IABP insertion in ICCU settings.
Material and methods: We retrospectively analyzed the data of
patients who received IABP insertion in our ICCU due to various
indications during January 2014–December 2014. We studied the
clinical details, indications of IABP insertion, complications and
their outcome. The outcome was noted in terms of all cause
mortality in ICCU, all causemortality during or after surgery during
index hospitalization and survival till discharge.
Results: During the above mentioned period, 35 patients under-
went IABP insertion out of which 26 (74.29%) were male, and
9 (25.71%) were females. Mean age of study population was 56
years. 33 (94.29%) patients came with acute STEMI, 1 (2.86%) had
myocarditis and 1 (2.86%) patient had acute severe MR secondary
to infective endocarditis. Out of 33 patients with STEMI, 17 (51.52%)
patients had cardiogenic shock due to pump failure, 6 (18.19%)
patients had post MI acute VSD, 4 (12.12%) patients had acute
ischemic severe MR, 2 (6.06%) patients had refractory ventricular
arrhythmias and 4 (12.12%) patients had refractory angina despite
full medical antianginal support.
17 (51.52%) patients had altered renal function in terms of
increased blood urea and serum creatinine before IABP insertion.
Average duration of IABP insertion was 2.3  1.2 days. During IABP
insertion, 9 (52.94%) patients developed leucocytosis, 3 (17.65%)
patients had anemia (1 required blood transfusion), 3 (17.65%)
patients had thrombocytopenia. Out of 17 patients who had
deranged renal function, 13 (76.47%) patients continued to have
renal dysfunction and 4 (23.53%) patients improved. However, 8
(47%) patients developed new onset renal dysfunction on IABP. 8
(22.86%) patients on IABP developed puncture site complications (3
had hematoma, 2 had limb ischemia and 3 had CVA). However
except for one patient with hematoma who required BT, all others
were managed conservatively. Out of 35 patients, 20 (57.14%)
patients died during index hospitalization (14 before surgery and
6 after surgery). 14 (40%) patients died in ICCU before they could
have been operated (pump failure-10, MI + VSD-3, MI + MR-1). One
patient of myocarditis was managed conservatively. Remaining 14
patients underwent surgery. During post surgery stay 6 (17.14%)
patients died (3 CABG patients, 2 CABG + VSD repair, ICABG
+ MVR). Out of 17 patients with deranged renal function on admis-
sion, 14 (82.35%) died.
Conclusion: Cardiogenic shock in acute MI setting continues to
have high mortality despite IABP support. Patients with impaired
renal function on admission are at particularly at higher risk for
mortality.
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Introduction: Left ventricular assist devices (LVADs) were origin-
ally developed as a temporary bridge to heart recovery and then
approved as bridge to Heart Transplant for End stage heart failure
patients falling in INTERMACS category 1, 2, and 3. Successful
outcomes with these indications justiﬁed usage of LVADs as des-
tination therapy. We report our initial experience on a series of 9
patients implanted with LVAD as destination therapy who were
either unsuitable for transplant or due to non-availability of sui-
table heart when patients were sick or as patient's choice with 4
months to 3 years follow-up.
Patient proﬁle: The hospital records of 11 patients implanted with
LVAD between Nov 2012 and Dec 2014 were retrospectively ana-
lyzed. There were 8 males and 3 females with age ranging from 26
to 51 years (mean – 47 years). 2 models of LVADs were implanted –
HEARTMATE–II (Thoratec-Axial Flow) in 3 patients and HEART-
WARE (HVAD – Centrifugal ﬂow) in 8 patients. Heart Mate 2 (infra-
diaphragmatic pocket) was chosen for body weight more than
70 kg and HEART WARE for low body weight patients (intraper-
icardial pocket, smaller device).
Basic diagnoses and clinical condition: Out of 11 patients 4 had
ischemic cardiomyopathy, one had recent anterior myocardial
infarction with recurrent VT and LV dysfunction, one had severe
valvular aortic stenosiswith severe LV dysfunction and other 3 had
dilated cardiomyopathy with severe heart failure. Other 2 patients
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